GlassScriptPhysician profile
Flerida L Tan
NPI 1316479991
$5,491.62
in general payments reported to CMS, 2019-2025
26 companies · $2,148 in 2025
The $2,148 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $220 · 2022: $349 · 2023: $935 · 2024: $1,839 · 2025: $2,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,632 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,632.10 |
| Education | $289.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $665.78 | 2023-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $546.98 | 2023-2025 | |
| Abbvie INC. | $539.38 | 2021-2025 | |
| Lilly USA, LLC | $536.96 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $459.14 | 2021-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $429.07 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $386.57 | 2022-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $256.97 | 2022-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $249.64 | 2022-2025 | |
| Pfizer INC. | $225.44 | 2021-2025 | |
| Incyte Corporation | $161.42 | 2024-2025 | Opzelura |
| Organon LLC | $149.34 | 2024-2025 | Hadlima, Vtama |
| Sun Pharmaceutical Industries INC. | $134.35 | 2023-2025 | Winlevi |
| Galderma Laboratories, L.P. | $133.81 | 2024-2025 | Nemluvio |
| Amgen INC. | $118.98 | 2022-2025 | Otezla, Otezla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $114.99 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $106.58 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $83.72 | 2021-2024 | Cabtreo, Jublia, Arazlo |
| Strata Skin Sciences, INC. | $53.88 | 2024-2025 | Xtrac |
| Botanix Sb INC | $35.13 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $30.30 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.40 | 2025 | Spevigo |
| Fresenius Kabi USA, LLC | $14.39 | 2023 | Idacio |
| Lnhc, INC | $14.18 | 2025 | Zelsuvmi |
| Dermavant Sciences, INC. | $13.12 | 2023 | Vtama |
| Journey Medical Corporation | $13.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Flerida Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.